Navigation Links
Max Nutrition, Inc. Completes Share Exchange with American Spring Pharmaceutical, Inc.
Date:1/31/2008

NEW YORK, Jan. 31 /Xinhua-PRNewswire-FirstCall/ -- Max Nutrition Inc. (OTC Bulletin Board: MXNU; the "Company") announced today that the Company has completed the share exchange (the "Closing") pursuant to an Agreement and Plan of Reorganization with American Spring Pharmaceutical, Inc., a Delaware corporation ("ASPI"). Pursuant to the Agreement, ASPI transferred 100% of the issued and outstanding shares of Gansu Biology Science and Technology Stock Co., Ltd ("GDBS") to the Company in exchange for 20,000,000 shares of the Company's common stock.

All of the present officers and directors of the Company resigned and Mr. Qi Jinjun, the Chairman and CEO of GDBS, became the sole officer and director of the Company.

"The completion of the share exchange is a great milestone in the development of GDBS; it symbolizes the first step of GDBS to become a truly global player in the fertilizer additive and livestock feed market," remarked Mr. Qi Jinjun. "In the future, we will continue to work hard and reaffirm our commitment to providing high quality fertilizer additives and animal feed for agricultural use."

ASPI, through its wholly owned operating subsidiary Gansu Dasheng Biology Science and Technology Stock Co., Ltd. (GDBS), a limited liability corporation organized under the laws of the People's Republic of China ("PRC"), engages in the development, production and distribution of additives for fertilizers and animal feed that have been enhanced through the addition of bacteria.

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks described in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the Company, are expressly qualified by the cautionary statements that may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

For more information, please contact:

Peter D. Zhou

Tel: +1-212-232-0120


'/>"/>
SOURCE Max Nutrition, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Healionics Corporation Completes Series A Financing
2. ActivBiotics Completes Sale of Fixed Assets; Expands Due Diligence Initiative for the Sale of Intellectual Property, Including Drug Product Candidates
3. Arno Therapeutics Completes License Agreements for the Exclusive Rights to Novel, Targeted Cancer Compounds
4. Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program
5. Quintiles Completes Previously Announced New Investor Partnership, Co-Led by Founder, Chairman and CEO Dennis Gillings, Bain Capital, TPG and 3i
6. CNS Response, Inc Completes Neuro-Therapy Clinic Acquisition; Names Daniel A. Hoffman, MD Chief Medical Officer
7. Abington Memorial Hospital Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology
8. China Medical Technologies Completes Acquisition of BBE
9. Boston Scientific Completes Sale of Cardiac Surgery and Vascular Surgery Businesses
10. Boston Scientific Completes Sale of Auditory Business and Drug Pump Development Program
11. Pharmos Corporation Completes Initial Closing of Private Placement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... ... release of LabKey’s newest software solution, LabKey Biologics . Built in collaboration ... and biotech organizations, LabKey Biologics provides drug research teams tools for biological entity ...
(Date:3/28/2017)... 28, 2017 Focus is ... sector due to the scientifically intensive operations of ... agricultural, environmental, and industrial. In today,s pre-market research, Stock-Callers.com ... Inc. (NASDAQ: PTLA), OvaScience Inc. (NASDAQ: OVAS), Ocera ... (NASDAQ: OCUL ). Learn more about ...
(Date:3/28/2017)... 28, 2017 /PRNewswire/ -RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: ... compelling safety and clinical data from its phase 1/2 tendon ... hair follicle-derived fibroblasts (RCT-01) as a treatment for Achilles tendinosis. ... ... safety profile at 6 months and showed no serious adverse ...
(Date:3/28/2017)... ... March 28, 2017 , ... Executive search firm, ... Avomeen Analytical Services. Harvill is a distinguished life sciences expert with a proven ... a leader in a wide range of services related to laboratory testing and ...
Breaking Biology Technology:
(Date:3/13/2017)... HAMBURG, Germany , March 13, 2017 Future of ... ... DERMALOGs Face Matching enables to match ... characteristics forms the basis to identify individuals. (PRNewsFoto/Dermalog Identification Systems) ... DERMALOG,s "Face Matching" is the fastest software for ...
(Date:3/7/2017)... Brandwatch , the leading social intelligence company, today announces that it ... insights to support its reporting, help direct future campaigns, and share ... charity will be using Brandwatch Analytics social listening and analytics technology ... the topics and issues that are a priority for its supporters. ... "Until recently we,ve ...
(Date:3/2/2017)... Summary This report provides all the ... interests and activities since 2010. ... Read the full report: http://www.reportlinker.com/p03605615-summary/view-report.html ... report provides an in-depth insight into the partnering activity of ... On demand company reports are prepared upon purchase to ensure ...
Breaking Biology News(10 mins):